In vitro susceptibility of carbapenem-resistant Enterobacterales to eravacycline - the first report from Croatia.
| Autor: | Jurić I; Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, Croatia., Bošnjak Z; Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia., Ćorić M; School of Medicine, University of Zagreb, Zagreb, Croatia.; Department of Gynaecology and Obstetrics, University Hospital Centre Zagre, Zagreb, Croatia., Lešin J; School of Medicine, University of Zagreb, Zagreb, Croatia.; Department of Gynaecology and Obstetrics, University Hospital Centre Zagre, Zagreb, Croatia., Mareković I; Department of Clinical and Molecular Microbiology, University Hospital Centre Zagreb, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of chemotherapy (Florence, Italy) [J Chemother] 2022 Feb; Vol. 34 (1), pp. 67-70. Date of Electronic Publication: 2021 Aug 17. |
| DOI: | 10.1080/1120009X.2021.1965335 |
| Abstrakt: | The main obstacle in treatment of infections caused by carbapenem-resistant Enterobacterales (CRE) are limited treatment options. The novel antimicrobial agents other than β-lactams with activity not being dependent on β-lactamase class are especially important. Eravacycline (ERV) is the first fully synthetic fluorocycline indicated for the treatment of complicated intra-abdominal infections in adults. Eighty CRE isolates at the University Hospital Centre Zagreb, Croatia were examined for susceptibility to ERV by disc diffusion method and minimal inhibitory concentration (MIC). Total of 54 (54/80; 67.5%) isolates were susceptible to ERV with MIC |
| Databáze: | MEDLINE |
| Externí odkaz: |
|